The results of the current trial, presented by Halperin at the annual scientific sessions of the American Heart Association, focused on patients with atrial fibrillation, a condition that increases the risk of stroke fivefold and afflicts 2 million Americans.

FORBES: Replacing Coumadin

Enhance focused on a group of 720 patients with a rare condition that made them susceptible to high cholesterol.

FORBES: Magazine Article